Sign In

Paulo Garcia

CEO & Co-Founder at Kytopen Corp.

Professional Background

Paulo Garcia is a dynamic and innovative leader in the field of biomedical engineering, serving as the CEO and co-founder of Kytopen Corp. His journey reflects an impressive combination of academic excellence, cutting-edge research, and entrepreneurial spirit. With a vision to revolutionize the way molecules are delivered into immune cells, Paulo has established Kytopen as a frontrunner in the commercialization of its proprietary Flowfect™ technology. This pioneering approach utilizes advanced microfluidics and automation, aimed specifically at enhancing the efficiency, speed, and reliability of cell engineering processes, which are crucial for the development of cost-effective cell and gene therapies.

Paulo's background as a Research Scientist at the prestigious Massachusetts Institute of Technology (MIT) has shaped his expertise and provided him with invaluable experience in the realms of bioengineering and biomedical science. Here, he co-invented the Flowfect™ technology—a testament to his innovative thinking and commitment to advancing the field of cell biology. With a meticulous approach to scientific inquiry and a deep understanding of complex biological systems, Paulo has not only made significant contributions to academia but is also poised to lead groundbreaking advancements in practical applications.

Education and Achievements

Paulo pursued his academic journey with passion and dedication, culminating in a Doctor of Philosophy (Ph.D.) in Bioengineering and Biomedical Engineering from Virginia Polytechnic Institute and State University. His doctoral studies allowed him to delve into intricate challenges within the field, equipping him with the knowledge to make impactful contributions.

Before obtaining his Ph.D., Paulo earned a Bachelor of Science (BS) degree in Physics from Randolph-Macon College. This foundational education in the physical sciences laid the groundwork for his subsequent explorations in bioengineering, enabling him to approach complex biological problems with a unique perspective and a rigorous analytical framework.

Achievements

Throughout his illustrious career, Paulo has been recognized for his innovative contributions to science and technology. His role at Kytopen includes not only leading the company but also driving the development of key strategies for the commercialization of Flowfect™ technology. This advanced platform has the potential to significantly streamline the cell engineering process, thereby promoting new discoveries in biology that can lead to transformative therapies for patients with a range of diseases.

In addition to his current leadership role, Paulo has a rich history of research and postdoctoral work at both the Massachusetts Institute of Technology and Virginia Tech, where he contributed to numerous academic projects and publications. His diverse experience spans across various roles, including that of a high school mathematics teacher at Benedictine High School, showcasing his commitment to education and mentorship.

Paulo Garcia continues to inspire those around him with his vision for the future of biotechnology and cell engineering. As he leads Kytopen towards its mission of enabling revolutionary advancements in healthcare, his expertise blends the realms of science, technology, and business, making him a prominent figure in the ongoing evolution of biomedical innovation.

Highlights

May 31 · linkedin

I’m happy to share that I’m starting a new position as CEO, President, & Board Director at BLASTID, Inc!

May 31 · linkedin

Honored and thrilled to join the Harvard start-up BLASTID, Inc as the incoming CEO, President, and Board Director. At BLASTID we are translating breakthrough innovations designed and led by our Co-Founder Dr. Johan Paulsson to transform the clinical diagnosis and treatment of bacterial infections (a leading cause of death worldwide). Beyond excited to partner with an industry pioneer Rahul Dhanda as a Co-Founder and Board Chair to further develop and commercialize these innovative technologies. I am grateful to have the opportunity to learn from and work with Eleftherios Mylonakis, an infectious disease ARPA-H DARTS clinical leader, in a collaboration to help demonstrate our patient benefit in a hospital setting. Energized to advance our active and future collaborations towards achieving meaningful global patient impact by tackling the unfolding crisis of antibiotic resistance as part of the largest grant ever received by Harvard (https://lnkd.in/euVX5DMx).   #innovation #spinout #partnerships #diagnostics #IVD #portalinnovations

Related Questions

How did Paulo Garcia co-invent the Flowfect™ technology during his time at MIT?
What are the key features of Kytopen's Flowfect™ technology that set it apart in the field of cell engineering?
How has Paulo Garcia's academic background influenced his approach to leading Kytopen Corp.?
In what ways does Paulo Garcia envision Flowfect™ technology impacting the future of cell and gene therapies?
What challenges did Paulo Garcia face when transitioning from academia to founding a biotechnology company?
How has Paulo Garcia's experience as a high school mathematics teacher shaped his leadership style at Kytopen?
Paulo Garcia
Add to my network

Location

Cambridge, Massachusetts, United States